Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Current Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Current Assets for 16 consecutive years, with $98.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 79.85% to $98.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $98.6 million, a 79.85% increase, with the full-year FY2024 number at $64.8 million, up 13.22% from a year prior.
  • Current Assets was $98.6 million for Q3 2025 at Gyre Therapeutics, up from $91.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $116.5 million in Q1 2021 to a low of $5.1 million in Q3 2023.
  • A 5-year average of $58.7 million and a median of $57.2 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: plummeted 90.63% in 2023, then soared 967.99% in 2024.
  • Gyre Therapeutics' Current Assets stood at $51.5 million in 2021, then dropped by 3.54% to $49.7 million in 2022, then rose by 15.24% to $57.2 million in 2023, then rose by 13.22% to $64.8 million in 2024, then soared by 52.16% to $98.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Current Assets are $98.6 million (Q3 2025), $91.3 million (Q2 2025), and $68.4 million (Q1 2025).